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ABSTRACT 
 Aim To determine the cost-effectiveness of corticosteroid injection, physiotherapy and a 
combination of these interventions, compared to a reference group receiving a blinded 
placebo injection. 
Methods 165 adults with unilateral lateral epicondylalgia of longer than six weeks duration 
from Brisbane, Australia were randomised using concealed allocation to saline injection 
(placebo), corticosteroid injection, saline injection plus physiotherapy (eight sessions of 
elbow manipulation and exercise) or corticosteroid injection plus physiotherapy. Costs to 
society and health-related quality of life (estimated by EuroQol-5D) over one year follow-up 
were used to generate incremental cost per quality-adjusted life year (QALY) ratios for each 
intervention relative to placebo.  
Results Intention to treat analysis was possible for 154 (93%) of trial participants. 
Physiotherapy was more costly, but was the only intervention that produced a statistically 
significant improvement in quality of life relative to placebo (MD, 95% CI 0.035, 0.003 to 
0.068). Similar cost/QALY ratios were found for physiotherapy (AUD29,343; GBP18,962) 
and corticosteroid injection (AUD31,750; GBP20,518), however the probability of being 
more cost-effective than placebo at values above AUD50 000 per quality-adjusted life year 
was 81% for physiotherapy and 53% for corticosteroid injection. Cost/QALY was far greater 
for a combination of corticosteroid injection and physiotherapy (AUD228,000; GBP147,340). 
Summary: Physiotherapy was a cost-effective treatment of lateral epicondylalgia. 
Corticosteroid injection was associated with greater variability, and a lower probability of 
being cost-effective if a willingness to pay threshold of AUD$50,000 is assumed. A 
combination of corticosteroid injection and physiotherapy was ineffective and cost-
ineffective. Physiotherapy, not corticosteroid injection, should be considered as a first line 
intervention for lateral epicondylalgia. 
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INTRODUCTION 
Lateral epicondylalgia (LE),  a common musculoskeletal condition, also known as tennis 
elbow, typically presents in the 4th-6th decade of life, and results in considerable individual 
morbidity and substantial healthcare utilization and lost time from work. It accounts for an 
estimated 0.3-1.1 medical consultations per year per 100 subjects of general practice,[2] 
while work absenteeism is documented in 5% of affected working adults, with a median 
duration of 29 days in the past 12 months.[3] 
 
There are no UK or Australian national guidelines or literary consensus for the optimal 
management for LE. Corticosteroid injection remains in widespread use,[4] despite 
systematic review evidence showing worse outcomes in the long term compared to a ‘wait 
and see’ approach or physiotherapy.[5] Inconsistent long term clinical benefits of 
physiotherapy are observed,[6,7] raising debate as to whether the surplus value of 
physiotherapy is worth the additional resources needed for treatment. On this basis, clinical 
guidelines were issued by the Dutch College of General Practitioners in 1997 recommending 
a wait and see policy, including advice and prescription of pain medication if necessary. 
More recently, guidelines were issued by the Swedish Counsel on Health Technology 
Assessment, strongly arguing against the use of corticosteroid injection.[8] 
 
The cost-effectiveness of competing therapeutic interventions for LE has been the subject of 
only two previous studies, both finding no significant differences.[9,10] A limitation of both 
of these trials was that the utilities that were used to generate cost-effectiveness ratios were 
derived from quality of life scores estimated at one year from baseline, whereas the costs 
were calculated over the entire one year period.  This risks measurement error in the cost-
effectiveness analysis denominator, by assuming that the health state over the preceding 12 
months was equal to that observed one year from baseline.  
 
We aimed to determine the cost-effectiveness of corticosteroid injection, physiotherapy and 
their combination by comparison with a reference group receiving placebo injection. 
 
METHODS 
Study design 
Economic evaluation was conducted alongside a randomised controlled trial, performed in a 
community setting in Brisbane, Australia. Full details of the trial design, participants, 
interventions and results of clinical outcomes are reported elsewhere.[11,12] The factorial-
design trial was powered to explore the long-term clinical efficacy of (1) corticosteroid 
versus placebo injection and (2) of adding physiotherapy to an injection. Differences in the 
analysis and reporting of clinical efficacy and economic evaluation are a reflection of the 
different research objectives.  
Study funding was received from the National Health and Medical Research Committee 
(Grant 511238) and a University of Queensland Research Scholarship, awarded to B.K.C. 
Ethical approval was gained from University of Queensland Medical Research Ethics 
Committee. Trial registration anzctr.org(#12609000051246). 
 
Patients 
Patients responding to media announcements between August 2008 and May 2010 were 
assessed for eligibility by telephone interview, followed by physical screening. Individuals 
were required to be 18 years or older and have experienced unilateral, lateral elbow pain for 
more than six weeks. A minimum pain intensity of 30mm on a 100mm visual analogue scale 
(VAS) was chosen to minimise floor effects and to ensure those with very mild pain were not 
subjected to unnecessary treatment. A clinical diagnosis of LE was defined as pain provoked 
by at least two of the following: gripping, palpation, resisted wrist or middle finger extension, 
or stretching of wrist extensor muscles with reduced pain-free grip. Patients were excluded if 
that had received any injection (preceding six months), a course of physiotherapy (preceding 
three months); concomitant neck or arm pain necessitating treatment or limiting usual 
activities (preceding six months); radicular, neurological or systemic symptoms; pregnancy; 
breastfeeding or contraindication to injection. 
Interventions 
Following written informed consent, 165 patients were randomly allocated by concealed 
allocation to one of four groups – saline injection (“placebo”), saline injection plus 
physiotherapy (“physiotherapy”), corticosteroid injection (“corticosteroid”) or corticosteroid 
injection plus physiotherapy (“combination”). Randomisation was stratified by high or low 
pain scores, based on a cut-off VAS of 65/100. One of five general practitioners injected 
either 0.5mL(0.9%) isotonic saline (placebo) or 10mg/1mL of triamcinolone acetonide plus 
1mL(1%) lignocaine (corticosteroid), in a manner that ensured the participant was blinded to 
the contents of the syringe. A previous dose-response study showed demonstrated similar 
results for 10mg triamcinolone compared to a higher dose (20mg), but with lower rates of 
skin atrophy (18% compared to 27%).[13]  Patients received standardised advice, 
recommending rest for 10-days, followed by gradual return to activity. They were 
discouraged from using other treatments, but were advised they could use over-the-counter 
analgesic or anti-inflammatory medication, forearm braces or heat or cold packs as needed. 
Participants allocated to receive physiotherapy underwent eight, 30-minute sessions of 
treatment by one of 11 post-graduate physiotherapists. Treatment was individually prescribed 
based on a standardised protocol.[12] It included manual therapy techniques at the elbow 
with gripping, concentric and eccentric wrist extension exercises, motor control retraining 
and global upper body strengthening. Each participant was asked to complete a daily home 
exercise program, which was reviewed by the physiotherapist at the commencement of each 
session, to monitor compliance and to progress the program.  
Resource utilisation and costing  
A societal viewpoint was used as the basis for economic evaluation, and as such included 
direct healthcare and non-healthcare costs, and indirect costs incurred due to LE, its treatment 
or any adverse events related to its treatment.[9] Costs for the one-year study period were 
derived from the following three sources and are reported in 2013 Australian dollars (1AUD 
=0.64623GDP, January 2013). Utilisation of study treatments was ascertained from medical 
records. Costs of medical services, including both government subsidies and patient co-
payments were obtained from the Medicare Australia database for the one-year follow-up 
period. Items listed as elbow, forearm or upper limb were included in analysis. All other 
resources/costs were collected via standardised telephone interviews,[14] administered by a 
research assistant blinded to health outcomes. At each of four randomly timed interviews, 
resources/costs incurred during the preceding month were recorded, and multiplied by three 
to generate annual costs. Where actual costs incurred were not available, costs were estimated 
as listed in Table 2.  
Quality of life 
Health-related quality of life was measured at baseline, 4, 8, 12, 26 and 52 weeks using the 
paper-based EuroQol-5D (EQ-5D) by an examiner blinded to treatment allocation.[9] 
Responses were converted to an overall utility score, by applying scoring weights based on 
the UK population.[15] Quality-adjusted life years (QALYs) were estimated for each 
individual using area-under-the-curve analysis with linear interpolation between 
observations.[16]  
 
Statistical analysis 
Sample size was based on primary clinical effects of corticosteroid injection and 
physiotherapy at one year.[11,12] Economic analysis was performed by intention-to-treat. As 
only one participant reported work absence, costs related to this were excluded for the base 
case analysis. Discounting was not applied, as the study duration was only12-months. 
 
Incremental costs and incremental QALYs (and 95% CI) were computed using generalised 
linear modelling (GLM) bias-corrected and accelerated bootstrapping with 2000 replications, 
with increments calculated as the intervention group value minus the placebo group value. 
Models were adjusted for baseline Patient Rated Tennis Elbow Evaluation (PRTEE) scores 
because of prognostic significance.[17] Adjustment for baseline utilities was also performed 
for estimation of incremental QALYs.[16] The primary outcome was the incremental cost-
effectiveness ratio (ICER), calculated by dividing the incremental cost by the incremental 
QALY. Uncertainty was explored by graphical display of cost-utility planes and acceptability 
curves.[18] Since cost-effectiveness analysis is a relative technique, we also compared our 
results to a theoretical ICER threshold of AUD$50,000 per QALY, consistent with previous 
studies.[19].  
 
Three sensitivity analyses were performed to test the robustness of assumptions. First, we 
tested the impact of including work absence, and second by excluding all productivity costs, 
as inclusion of lost productivity as a cost is considered controversial,[20]. Third, we tested 
the effect of alternative calculation of medical costs, using self-reported costs/resources. 
 
Statistical analysis was performed using STATA 13.1 for Mac (StataCorp, 2014), and cost-
utility planes and acceptability curves were generated using Excel for Mac 14.4.5 (Microsoft, 
2011).  
RESULTS 
The flow of participants leading to economic analysis of 154 (93%) participants is illustrated 
in Figure 1. There were no significant differences at baseline between participants included 
(n=154) and excluded (n=11) from analysis. Per protocol resources were available for all 
participants, while 3.9% of interviews (25/644) were missing, with no differences between 
treatments or between survey periods. Six people missed a single interview, and estimates 
were replaced using the mean of their three completed interviews. Five people did not 
complete any interviews and were excluded from the analysis. Medical Benefit Schedule data 
was missing or ineligible for 5% participants, because of international residence (n=5), non-
consent (n=1) or invalid paperwork (n=3). Quality of life estimates were missing for 2.4% 
individuals, because of death (n=2) or loss to follow up (n=2) and were excluded from 
analysis. Demographic and injury characteristics did not differ between groups at baseline 
(Table 1).  
Table 1: Baseline characteristics 
Characteristic Placebo 
Physiotherapy 
+ Placebo Corticosteroid 
Corticosteroid + 
Physiotherapy 
 
P 
n Analysed 39 39 40 36 
 Age (years) 49.8 (7.5) 48.9 (7.7) 49.7 (9.0) 50.7 (8.6) 0.813 
Female, n (%) 15 (38%) 14 (36%) 15 (38%) 14 (39%) 0.993 
Duration (median (IQR), weeks) 16 (8,32) 16 (8, 26) 16 (10, 28) 13 (10, 26) 0.217 
Worst pain (VAS: 0-100) 62.0 (19.7) 63.0 (18.3) 61.6 (19.4) 59.3 (15.8) 0.844 
Resting pain (VAS: 0-100) 13.9 (16.1) 7.9 (9.2) 11.9 (16.1) 9.7 (10.3) 0.225 
Pain & disability  (PRTEE: 0-100) 42.2 (14.5) 36.4 (13.1) 41.1 (13.8) 38.2 (12.9) 0.224 
Quality of life (EQ-5D: 0-1) 0.737 (0.122) 0.744 (0.125) 0.692 (0.175) 0.755 (0.036) 0.139 
Annual income (AUD) 77390 (51843) 65031 (46171) 57439 (37453) 65135 (39549) 0.253 
Nil income, n (%) 4 (10%) 4 (10%) 2 (5%) 1 (3%) 0.448 
Data represents mean (SD) or count (%), unless otherwise stated. Differences between groups were analysed using Analysis of Variance or 
Pearson Chi-square statistic. PRTEE: Patient rated tennis elbow evaluation, EQ-5D: Euroqol questionnaire. 
 
Costs  
Mean costs per individual (excluding work absence) for each group were: $173 for placebo, 
$295 for corticosteroid, $1177 for physiotherapy and $1069 for corticosteroid plus 
physiotherapy (Table 2). Incremental costs showed that all interventions were significantly 
more costly than placebo (Table 3; P<0.035). Baseline pain and disability (PRTEE score) 
was a significant independent predictor of societal costs, with greater costs incurred by 
individuals with higher pain and disability at baseline (β 4.0, 95% CI 0.3, 7.6; P=0.034). No 
participants required surgery or prescribed medication. 
Table 2: One-year costs to society and quality-adjusted life years (QALYs).  
Resource Data source  Placebo 
Physiotherapy 
+ Placebo Corticosteroid 
Corticosteroid + 
Physiotherapy 
 
P 
Direct healthcare costs (total)   $101 (5) $673 (102) $159 (245) $636 (143) <0.001* 
Per protocol medical $100 per visit a $100 (0) $100 (0) $100 (0) $100 (0) NA 
Per protocol physiotherapy $75 per visit a - $569 (97) - $515 (118) 0.031* 
Non protocol medical (MBS) Real costs b $1 (5) $0 (0) $20 (49) $7 (25) 0.008* 
Non protocol other Real costs c $0 (0) $4 (26) $39 (215) $14 (58) 0.42 
Direct non-healthcare costs (total)   $34 (108) $144 (169) $78 (204) $100 (32) 0.01* 
Over the counter medication Real costs c $3 (11) $3 (13) $19 (38) $4 (16) 0.004* 
Assistive devices (e.g., brace, 
ultrasound, hotpack) Real costs c $0 (0) $ 11 (33) $37 (161) $0 (0) 0.168 
Paid or unpaid labour $36.33 per hr c, d $18 (108) $23 (122) $0 (0) $0 (0) 0.481 
Per protocol transportation  $0.63 per km c, e $13 (0) $106 (15) $13(0) $94 (19) <0.001* 
Non protocol transportation $0.63 per km c, e  $0 (0) $0.2 (1.5) $9 (34) $2 (9) 0.059 
Indirect costs (total)   $38 (0) $360 (57) $157 (626) $333 (75) 0.001* 
Time loss due to work absence  Individual rate c, f $0 (0) $0 (0) $99 (627) $0 (0) 0.419 
Per protocol leisure time loss f $36.33 per hr c, g $38 (0) $358 (54) $38 (0) $327 (66) <0.001* 
Non protocol leisure time loss  $36.33 per hr c, g $0 (0) $2 (13) $20 (54) $6 (25) 0.017* 
Societal costs excluding work 
absence    $173 (108) $1177 (251) $295 (372) $1069 (244) <0.001* 
Societal costs (total)   $173 (108) $1177 (251) $394 (708) $1069 (244) <0.001* 
QALYs   0.880 (0.092) 0.920 (0.075) 0.873 (0.078) 0.891 (0.084) 0.069 
Values represent mean (SD) per participant for each group. Costs are AUD. Differences between groups were examined using Analysis of 
Variance, with significant (<0.05) differences marked by an asterisk.  
a Rate paid to practitioners taking part in the study;  
b Costs determined by Medicare Benefits Schedule (MBS) items listed as either elbow, forearm or upper limb;  
c Resources/costs derived from interview, multiplied by three to give annual estimates;  
d Shadow price based on average weekly earnings for an adult ($1453 per 40 hour week) from the Australian Bureau of Statistics (2012).  
e Mean travel distances for medical (19.9km) and physiotherapy appointments (18.9km) were multiplied by $0.63/km, based on private 
vehicle reimbursement rate by the Australian Taxation Office (2011), plus any other out-of-pocket transport costs; 
f Total days of work absence were multiplied by the respondent-specific hourly rate; 
g Mean (appointment plus travel) times per session for medical (62.4min) and physiotherapy (69.5min)  
 
Table 3: Incremental costs and incremental quality-adjusted of life years (QALY) for 
physiotherapy, corticosteroid injection and their combination, compared to a reference 
group receiving placebo injection.  
 
Physiotherapy + 
Placebo Corticosteroid 
Corticosteroid + 
Physiotherapy 
Incremental QALY (95% CI); P 0.035 (0.003, 0.068)* 0.004 (-0.030, 0.039) 0.004 (-0.032, 0.041) 
Base case - Societal costs excluding work absence 
  Incremental cost (95% CI)  $1027 (941,1113)*   $127 (9, 245)*   $912 (822, 1002)* 
Cost per QALY (ICER) $29,343 $31,750 $228,000 
Probability ICER < $50,000 a 81% 53% 24% 
Sensitivity 1 - Societal costs inclusive of work absence 
  Incremental cost (95% CI)  $1027 (941,1113)*   $226 (5, 447)*   $912 (822, 1002)* 
Cost per QALY (ICER) $29,343 $56,500 $228,000 
Probability ICER < $50,000 a 81% 48% 24% 
Sensitivity 2 - Direct healthcare & non-healthcare costs, i.e., productivity costs excluded 
Incremental cost (95% CI); P  $702 ($627, 776)*   $106 (2, 209)*   $615 (545, 684)*  
Cost per QALY (ICER) $20,057 $26,500 $153,750 
Probability ICER < $50,000 a 90% 53% 34% 
Sensitivity 3 - Medical costs derived from interview 
 Incremental cost (95% CI); P  $1028 (940,1116)*   $182 (6, 359)*   $905 (817, 994)* 
Cost per QALY (ICER) $29,371 $45,500 $226,250 
Probability ICER < $50,000 a 81% 50% 24% 
Confidence intervals were calculated using generalized linear modelling with bias corrected bootstrapping (2000 replicates), adjusted for 
baseline scores of pain and disability, using the Patient rated tennis elbow evaluation. Incremental QALY was adjusted for baseline EQ-5D 
utilities. Significant (P<0.05) differences compared to placebo are marked with an asterisk. ICER: Incremental cost-effectiveness ratio 
calculated as incremental cost divided by incremental quality-adjusted life year. a Probability that the intervention is more cost-effective than 
placebo at an ICER threshold of AUD$50,000. 
 
The major contributors to direct healthcare costs, productivity costs and travel expenses were 
physiotherapy-driven. Participants assigned to physiotherapy plus placebo completed an 
average of 7.6 sessions (range 1-9), while significantly (P=0.031) fewer sessions were 
completed by those assigned to corticosteroid plus physiotherapy (mean 6.9, range 2-9). Non-
protocol medical costs (derived from Medicare database) and over-the-counter medication 
costs also differed between groups, with higher costs incurred by participants assigned to 
corticosteroid injection. Costs of other appointments, not listed by the Medicare, such as 
shockwave therapy, physiotherapy, chiropractic and massage, were also highest in 
participants assigned to corticosteroid although differences did not reach significance. 
Quality of life 
Utilities estimated over the one-year follow up for the four interventions ranged from 0.873 
to 0.920 (Table 2). Incremental QALYs (Table 3) showed significantly greater benefit for 
physiotherapy plus placebo (P=0.032), but not corticosteroid (P=0.746) or corticosteroid 
plus physiotherapy (P=0.743) when compared to placebo. Baseline EQ-5D was a significant 
independent predictor of one-year QALY (β 0.25, 95% CI 0.13, 0.37; P<0.001). 
Cost-effectiveness 
Incremental cost/QALY ratios were $29,343 for physiotherapy, $31,750 for corticosteroid 
and $228,000 for corticosteroid plus physiotherapy (Table 3). Cost-utility planes and 
acceptability curves are illustrated in Figures 2A-2C and 3 respectively. For physiotherapy, 
increased costs and increased benefits were seen (Figure 2A). For both corticosteroid and 
corticosteroid plus physiotherapy groups, bootstrapped cost-utility pairs straddled the 
northern quadrants, indicating increased costs but considerable uncertainty regarding the 
health benefits. For corticosteroid injection, a small minority (1%) of cost-utility pairs were 
located in the southeast quadrant, indicating cost saving and increased effectiveness 
compared to placebo (Fig 2B). At a threshold of $50,000/QALY, the probability of being 
more cost-effective than placebo, was 81% for physiotherapy, 53% for corticosteroid and 
24% for corticosteroid plus physiotherapy (Figure 3). Thus, at this threshold, physiotherapy 
was more likely to be cost-effective than the alternatives. 
Sensitivity analysis 
Inclusion of costs associated with work absence increased the incremental cost/QALY to $56, 
500 for corticosteroid, while the probability of being cost-effective at the $50,000 threshold 
fell to 48%. When all productivity costs were excluded, cost/QALY fell for all groups, to 
$20,057 for physiotherapy plus placebo, $26,500 for corticosteroid and $153,750 for the 
combination intervention. Probabilities rose to 90% and 34% for physiotherapy plus placebo 
and corticosteroid injection plus physiotherapy respectively, while was unchanged (53%) for 
the corticosteroid group. Alternative analysis of medical costs showed similar cost/QALY 
estimates for physiotherapy plus placebo ($29,371) and corticosteroid plus physiotherapy 
($226,250), with no change in their probabilistic estimates. However, self-reported data 
produced greater cost/QALY ($45,500) and lower probability (50%) for corticosteroid. 
 
DISCUSSION 
Rigorous research relating to cost-effectiveness of treatments in sports medicine is a nascent 
field.[21] The cost-effectiveness of a single corticosteroid injection, eight weeks of 
physiotherapy, and a combination of the two interventions were each compared with a 
reference group receiving a blinded, placebo injection.  Physiotherapy, had greater initial 
costs due eight treatment sessions, but was the only intervention that resulted in significantly 
greater quality of life. Corticosteroid injection demonstrated considerable variability in 
quality of life benefits over one year and higher non-protocol costs. Corticosteroid plus 
physiotherapy produced both high costs and considerable variability in outcomes. 
 
Potential economic impact if implemented as policy 
The resultant incremental cost/QALY ratios ranged from AUD20,057 to 29,371 
(GDP12,961-18,980) for physiotherapy and from AUD26,500 to 56,500 (GBP17,125-36,512) 
for corticosteroid injection. Placed in perspective, these willingness to pay per QALY values 
would be unlikely to be rejected by the Australian Pharmaceutical Benefits Advisory 
Committee (PBAC)[22] or UK National Institute of Health and Care Excellence (NICE)[23] 
and would be considered highly cost-effective by the World Health Organisation (WHO) 
(<1xGPD per capita).[24] [Australia’s GDP per capita in 2013 was AUD75,348]. In contrast, 
cost/QALY ratios for corticosteroid injection plus physiotherapy ranged from AUD153,750 
to 228,000 (GDP99,358-147,340), and would be considered not cost-effective, based on 
WHO (>3xGDP per capita)[24], PBAC[22] or NICE[23] guidelines.  
 
Probabilistic sensitivity analyses suggest that physiotherapy is highly likely (81-90%) to be 
considered a cost-effective intervention for LE when a threshold of AUD50,000 or greater is 
applied. In comparison, we found much greater uncertainty (48-65% probability) as to 
whether corticosteroid injection provides better value for money than placebo. 
The results of this study have important implications for health economic policy. Conclusions 
are in agreement with a large body of clinical evidence,[5-7] that states corticosteroid 
injection should not be recommended as a first line intervention for LE. Given 48% of 
surveyed UK specialists continue to use corticosteroid injection as a first line intervention for 
LE, and half stated they had not changed their practice in light of recent evidence, it appears 
penetrance of the latest evidence remains poor.[4,25] 
 
Economic analysis alongside another randomised controlled trial conducted in the 
Netherlands, estimated the societal cost/QALY for a six week physiotherapy program 
consisting of ultrasound, massage and exercise, to be 34,000Euro compared to a ‘wait and 
see’ approach.[9] Analysis of uncertainty showed 55% of cost-utility pairs were located in the 
northeast quadrant, indicating physiotherapy produced greater costs and QALYs, while 12% 
were located in the southeast quadrant indicating cost saving and improved QALY. 
Corticosteroid injection was less costly, but also less effective than wait and see, with a 
resulting cost/QALY of approximately 7000Euro.There are likely several potential sources of 
heterogeneity when comparing the cost-effectiveness of interventions between these trials. 
Differences in physiotherapy protocols and the reference group studied, as well as differences 
in recruitment and healthcare settings, may influence findings. The Dutch trial recruited 
patients who had visited a general medical practitioner for their elbow condition, while our 
trial recruited participants from the general community. We found much lower self-reported 
work absence than other published reports,[3,9,10] which may be in part due to our study 
eligibility requirements where participants were excluded if they had received treatments for 
their elbow within the preceding six months. Methodological differences between the two 
trials should also be considered. Korthals de Bos (2004) compared costs incurred over one 
year with quality of life estimated at one year from baseline,[9] hence may not have captured 
the early benefits of treatments. 
 
Strengths & limitations 
The strengths of our trial are its methodological rigor, comprehensive estimation of costs and 
low missing data (≤5%). To minimise recall bias, as well as burden on participants and 
researchers, we randomly sampled participants four times over one year, asking them to 
recall resources/costs over the previous month.[26] Several sources were used to determine 
costs, because there is no gold standard measurement.[26] Sensitivity analysis was used to 
examine the agreement between self-reported and administrative (Medicare) data. A 
limitation of data from the Medicare Benefits Schedule is that general practitioner and 
specialist services for LE cannot be distinguished from those for other conditions. Radiology 
services could be distinguished by their item codes, allowing only those listed as upper limb 
or forearm to be included in cost estimations. This may have led to conservative estimation of 
the utilisation of LE-related medical services. Sensitivity analysis using medical costs derived 
from interview resulted in a higher cost/QALY estimate for corticosteroid injection, but did 
not change those for physiotherapy or corticosteroid plus physiotherapy. We also evaluated 
the impact of productivity losses, by excluding the opportunity cost of lost leisure time. 
Whilst cost/QALY estimates improved for all interventions, study conclusions were robust to 
the different perspective.  
Several caveats should be noted that might affect the generalizability of study findings. In 
this trial, incremental costs and benefits for each intervention were each compared with a 
reference group that received a blinded injection of a negligible volume of normal saline, as 
well as standardised advice and analgesic medication. Although a placebo injection is not 
consistent with either usual care or a ‘wait and see’ policy, the pattern of recovery of primary 
clinical outcomes appears very similar.[6,7] Second, due to the nature of the physiotherapy 
intervention, it was not possible to blind the physiotherapists and patients, which may have 
introduced a bias, although both were blinded to the injection received. Third, costs could 
probably be reduced, and cost-effectiveness potentially improved, by reducing the number of 
physiotherapy sessions. Our protocol recommended eight sessions of physiotherapy, while 
others have used six.[6] Reducing the number of sessions reduces direct healthcare and non-
healthcare costs, as well as opportunity costs from lost leisure time. Further research is 
needed to ascertain whether similar benefits can be achieved with fewer treatment sessions. 
Last, societal costs were found to be independently associated with baseline pain and 
disability, a known prognostic risk factor.[17,27] Future research should consider whether 
allocation to a wait and see policy or physiotherapy treatment based on risk of chronicity may 
allow for more cost-effective resource use. Such an approach for primary care management 
of low-back pain was found to be highly cost-effective when compared to current best 
practice.[28]  
 
What is already known 
• Corticosteroid injection leads to short term clinical benefits but poorer long term 
outcomes than wait and see or physiotherapy. 
• There is little evidence for the cost-effectiveness of interventions for patients with 
lateral epicondylalgia 
 
What this study adds 
• Physiotherapy is highly likely to be considered a cost-effective treatment for lateral 
epicondylalgia. 
• The cost effectiveness of corticosteroid injection is more uncertain, while the 
combination of corticosteroid injection and physiotherapy is neither clinically nor 
cost-effective.  
 
How might this study impact on clinical practice 
• Clinical and economic evidence both advise against use of corticosteroid injection as 
a first line intervention for lateral epicondylalgia. 
 
 
Figure 1 Flow of participants from randomisation to economic analysis of 154 (93%) 
participants by intention to treat (ITT). QALY: Health-related quality of life. 
 
Figure 2 Cost-utility planes for corticosteroid injection, physiotherapy or their combination, 
compared to the reference placebo group. Data represents 2000 bootstrapped cost and effect 
pairs. For the base-case analysis presented here, costs to society (AUD), excluding work 
absence were used. QALYs: Quality-adjusted life years. 
 
Figure 3 Incremental cost-effectiveness acceptability curves for corticosteroid, physiotherapy 
or their combination, compared to the reference placebo group. For the base-case analysis 
presented here, costs to society, excluding work absence were used. Costs are reported in 
2013 Australian dollars (1AUD =0.64623GDP, January 2013). QALYs: Quality-adjusted life 
years. 
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